联合治疗-话题@MedSci

#联合治疗#

277篇内容 | 4248人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1313761, encodeId=4dc41313e61bb, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=2019 WCLC | NSCLC一线治疗进展：双免疫联合治疗在晚期NSCLC 安全性探索, objectType=article, longId=179497, objectId=19c31e9497c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19c31e9497c1, replyNumber=0, likeNumber=75, createdTime=2019-09-17, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19c31e9497c1, moduleTitle=2019 WCLC | NSCLC一线治疗进展：双免疫联合治疗在晚期NSCLC 安全性探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19c31e9497c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313760, encodeId=f3271313e60bf, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=J Hepatology：普伐他汀与索拉非尼联合治疗并未改善晚期肝细胞癌的生存率, objectType=article, longId=179354, objectId=69551e93547e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69551e93547e, replyNumber=0, likeNumber=62, createdTime=2019-09-14, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69551e93547e, moduleTitle=J Hepatology：普伐他汀与索拉非尼联合治疗并未改善晚期肝细胞癌的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69551e93547e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313759, encodeId=c49e1313e5939, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JCC：低剂量甲氨蝶呤与抗TNF联合治疗炎症性肠病与使用大剂量甲氨蝶呤具有相似的疗效, objectType=article, longId=178612, objectId=38331e861223, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38331e861223, replyNumber=0, likeNumber=69, createdTime=2019-09-04, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38331e861223, moduleTitle=JCC：低剂量甲氨蝶呤与抗TNF联合治疗炎症性肠病与使用大剂量甲氨蝶呤具有相似的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38331e861223)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313758, encodeId=de5a1313e589d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Xynomic公司宣布其HDAC抑制剂Abbexinostat与Keytruda联合治疗多种实体瘤的阳性1b期研究中期数据, objectType=article, longId=178550, objectId=07b01e855010, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07b01e855010, replyNumber=0, likeNumber=66, createdTime=2019-09-03, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07b01e855010, moduleTitle=Xynomic公司宣布其HDAC抑制剂Abbexinostat与Keytruda联合治疗多种实体瘤的阳性1b期研究中期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07b01e855010)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313757, encodeId=14721313e5773, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Lancet：布地奈德-福莫特罗联合治疗用于轻中度哮喘患者恶化预防, objectType=article, longId=178254, objectId=242c1e8254fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=242c1e8254fc, replyNumber=0, likeNumber=70, createdTime=2019-08-29, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=242c1e8254fc, moduleTitle=Lancet：布地奈德-福莫特罗联合治疗用于轻中度哮喘患者恶化预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=242c1e8254fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313756, encodeId=c7621313e56c9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点, objectType=article, longId=178209, objectId=6ad01e8209da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad01e8209da, replyNumber=0, likeNumber=53, createdTime=2019-08-27, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad01e8209da, moduleTitle=JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ad01e8209da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313755, encodeId=10521313e5526, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=FDA加速批准了强生的SIRTURO（bedaquiline）作为联合治疗的一部分，用于肺部多重耐药结核病感染的青少年, objectType=article, longId=177571, objectId=43a21e757124, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43a21e757124, replyNumber=0, likeNumber=68, createdTime=2019-08-15, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43a21e757124, moduleTitle=FDA加速批准了强生的SIRTURO（bedaquiline）作为联合治疗的一部分，用于肺部多重耐药结核病感染的青少年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43a21e757124)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313754, encodeId=a7491313e544d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Oncologie宣布与Merck进行临床试验合作，评估Bavituximab与PD-1单抗KEYTRUDA联合治疗晚期胃癌或胃食管癌, objectType=article, longId=177568, objectId=24091e7568e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24091e7568e4, replyNumber=0, likeNumber=65, createdTime=2019-08-15, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24091e7568e4, moduleTitle=Oncologie宣布与Merck进行临床试验合作，评估Bavituximab与PD-1单抗KEYTRUDA联合治疗晚期胃癌或胃食管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24091e7568e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313753, encodeId=c9ed1313e5327, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=AP&T：硫代嘌呤-别嘌呤醇联合治疗炎症性肠病安全性的研究, objectType=article, longId=177417, objectId=13c01e74173a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13c01e74173a, replyNumber=0, likeNumber=68, createdTime=2019-08-12, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13c01e74173a, moduleTitle=AP&T：硫代嘌呤-别嘌呤醇联合治疗炎症性肠病安全性的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13c01e74173a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313752, encodeId=e4881313e52bb, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人, objectType=article, longId=177126, objectId=a2121e71269e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2121e71269e, replyNumber=0, likeNumber=70, createdTime=2019-08-09, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2121e71269e, moduleTitle=罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2121e71269e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313751, encodeId=5e3b1313e5179, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=结直肠癌治疗新进展：靶向治疗精准护航，联合治疗引领新方向, objectType=article, longId=177122, objectId=a0e11e712277, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0e11e712277, replyNumber=0, likeNumber=67, createdTime=2019-08-09, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0e11e712277, moduleTitle=结直肠癌治疗新进展：靶向治疗精准护航，联合治疗引领新方向, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0e11e712277)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313750, encodeId=84f01313e5004, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=“T+A”，也许就是要找的那个TA？解读肝癌免疫联合治疗的时代强大音, objectType=article, longId=176410, objectId=cd331e6410bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd331e6410bd, replyNumber=0, likeNumber=70, createdTime=2019-07-30, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd331e6410bd, moduleTitle=“T+A”，也许就是要找的那个TA？解读肝癌免疫联合治疗的时代强大音, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd331e6410bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313749, encodeId=91a31313e49d0, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, objectType=article, longId=176189, objectId=bfbc1e6189e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfbc1e6189e0, replyNumber=0, likeNumber=56, createdTime=2019-07-27, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfbc1e6189e0, moduleTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfbc1e6189e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313748, encodeId=dc2e1313e48a2, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Clin Gastroenterology H：英夫利昔单抗和硫唑嘌呤联合治疗可改善英夫利昔单药代动力学特征和疗效, objectType=article, longId=175464, objectId=2f6d1e546456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f6d1e546456, replyNumber=0, likeNumber=66, createdTime=2019-07-16, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f6d1e546456, moduleTitle=Clin Gastroenterology H：英夫利昔单抗和硫唑嘌呤联合治疗可改善英夫利昔单药代动力学特征和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f6d1e546456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313747, encodeId=c8c71313e4781, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Diabetes Obes Metab：胰岛素和GLP-1联合治疗的长期疗效和安全性, objectType=article, longId=175060, objectId=fc3f1e5060e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc3f1e5060e3, replyNumber=0, likeNumber=25, createdTime=2019-07-10, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc3f1e5060e3, moduleTitle=Diabetes Obes Metab：胰岛素和GLP-1联合治疗的长期疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc3f1e5060e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313746, encodeId=ad841313e4669, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=J Clin Oncol：突破，完全缓解率71%！卡瑞利珠单抗联合治疗复发难治霍奇金淋巴瘤新进展, objectType=article, longId=168859, objectId=79c5168859a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79c5168859a5, replyNumber=0, likeNumber=54, createdTime=2019-06-22, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79c5168859a5, moduleTitle=J Clin Oncol：突破，完全缓解率71%！卡瑞利珠单抗联合治疗复发难治霍奇金淋巴瘤新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79c5168859a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313745, encodeId=ddcd1313e452e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=中国成人2型糖尿病口服降糖药联合治疗专家共识, objectType=article, longId=168628, objectId=5a731686285b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a731686285b, replyNumber=0, likeNumber=20, createdTime=2019-06-18, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a731686285b, moduleTitle=中国成人2型糖尿病口服降糖药联合治疗专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a731686285b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313744, encodeId=f60c1313e44fb, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=消化道肿瘤治疗：免疫与靶向治疗是热点，联合治疗是方向, objectType=article, longId=168403, objectId=7dcc16840325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7dcc16840325, replyNumber=0, likeNumber=76, createdTime=2019-06-15, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dcc16840325, moduleTitle=消化道肿瘤治疗：免疫与靶向治疗是热点，联合治疗是方向, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7dcc16840325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313743, encodeId=c89b1313e43f9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=双免疫联合治疗消化道肿瘤新进展, objectType=article, longId=168274, objectId=6ccf1682e4f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ccf1682e4f0, replyNumber=0, likeNumber=89, createdTime=2019-06-14, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ccf1682e4f0, moduleTitle=双免疫联合治疗消化道肿瘤新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ccf1682e4f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313742, encodeId=af341313e4285, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=免疫单药或联合治疗进军肺癌，免疫治疗再下一城？, objectType=article, longId=168210, objectId=56df168210a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56df168210a1, replyNumber=0, likeNumber=61, createdTime=2019-06-14, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56df168210a1, moduleTitle=免疫单药或联合治疗进军肺癌，免疫治疗再下一城？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56df168210a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合治疗

2020-05-29

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

2019 WCLC | NSCLC一线治疗进展：双免疫联合治疗在晚期NSCLC 安全性探索

2019-09-17

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

J Hepatology：普伐他汀与索拉非尼联合治疗并未改善晚期肝细胞癌的生存率

2019-09-14

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

JCC：低剂量甲氨蝶呤与抗TNF联合治疗炎症性肠病与使用大剂量甲氨蝶呤具有相似的疗效

2019-09-04

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Xynomic公司宣布其HDAC抑制剂Abbexinostat与Keytruda联合治疗多种实体瘤的阳性1b期研究中期数据

2019-09-03

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Lancet：布地奈德-福莫特罗联合治疗用于轻中度哮喘患者恶化预防

2019-08-29

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点

2019-08-27

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

FDA加速批准了强生的SIRTURO（bedaquiline）作为联合治疗的一部分，用于肺部多重耐药结核病感染的青少年

2019-08-15

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Oncologie宣布与Merck进行临床试验合作，评估Bavituximab与PD-1单抗KEYTRUDA联合治疗晚期胃癌或胃食管癌

2019-08-15

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

AP&T：硫代嘌呤-别嘌呤醇联合治疗炎症性肠病安全性的研究

2019-08-12

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人

2019-08-09

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

结直肠癌治疗新进展：靶向治疗精准护航，联合治疗引领新方向

2019-08-09

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

“T+A”，也许就是要找的那个TA？解读肝癌免疫联合治疗的时代强大音

2019-07-30

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点

2019-07-27

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Clin Gastroenterology H：英夫利昔单抗和硫唑嘌呤联合治疗可改善英夫利昔单药代动力学特征和疗效

2019-07-16

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Diabetes Obes Metab：胰岛素和GLP-1联合治疗的长期疗效和安全性

2019-07-10

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

J Clin Oncol：突破，完全缓解率71%！卡瑞利珠单抗联合治疗复发难治霍奇金淋巴瘤新进展

2019-06-22

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

中国成人2型糖尿病口服降糖药联合治疗专家共识

2019-06-18

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

消化道肿瘤治疗：免疫与靶向治疗是热点，联合治疗是方向

2019-06-15

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

双免疫联合治疗消化道肿瘤新进展

2019-06-14

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

免疫单药或联合治疗进军肺癌，免疫治疗再下一城？

2019-06-14

科室
- - 订阅+
  - 更多科室
工具
服务